Search tips
Search criteria 


Logo of jcinvestThe Journal of Clinical Investigation
J Clin Invest. 1997 August 1; 100(3): 705–712.
PMCID: PMC508240

Activators of the nuclear hormone receptors PPARalpha and FXR accelerate the development of the fetal epidermal permeability barrier.


Members of the superfamily of nuclear hormone receptors which are obligate heterodimeric partners of the retinoid X receptor may be important in epidermal development. Here, we examined the effects of activators of the receptors for vitamin D3 and retinoids, and of the peroxisome proliferator activated receptors (PPARs) and the farnesoid X-activated receptor (FXR), on the development of the fetal epidermal barrier in vitro. Skin explants from gestational day 17 rats (term is 22 d) are unstratified and lack a stratum corneum (SC). After incubation in hormone-free media for 3-4 d, a multilayered SC replete with mature lamellar membranes in the interstices and a functionally competent barrier appear. 9-cis or all-trans retinoic acid, 1,25 dihydroxyvitamin D3, or the PPARgamma ligands prostaglandin J2 or troglitazone did not affect the development of barrier function or epidermal morphology. In contrast, activators of the PPARalpha, oleic acid, linoleic acid, and clofibrate, accelerated epidermal development, resulting in mature lamellar membranes, a multilayered SC, and a competent barrier after 2 d of incubation. The FXR activators, all-trans farnesol and juvenile hormone III, also accelerated epidermal barrier development. Activities of beta-glucocerebrosidase and steroid sulfatase, enzymes previously linked to barrier maturation, also increased after treatment with PPARalpha and FXR activators. In contrast, isoprenoids, such as nerolidol, cis-farnesol, or geranylgeraniol, or metabolites in the cholesterol pathway, such as mevalonate, squalene, or 25-hydroxycholesterol, did not alter barrier development. Finally, additive effects were observed in explants incubated with clofibrate and farnesol together in suboptimal concentrations which alone did not affect barrier development. These data indicate a putative physiologic role for PPARalpha and FXR in epidermal barrier development.

Full Text

The Full Text of this article is available as a PDF (637K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Elias PM, Menon GK. Structural and lipid biochemical correlates of the epidermal permeability barrier. Adv Lipid Res. 1991;24:1–26. [PubMed]
  • Downing DT. Lipid and protein structures in the permeability barrier of mammalian epidermis. J Lipid Res. 1992 Mar;33(3):301–313. [PubMed]
  • Harpin VA, Rutter N. Barrier properties of the newborn infant's skin. J Pediatr. 1983 Mar;102(3):419–425. [PubMed]
  • Vernon HJ, Lane AT, Wischerath LJ, Davis JM, Menegus MA. Semipermeable dressing and transepidermal water loss in premature infants. Pediatrics. 1990 Sep;86(3):357–362. [PubMed]
  • Freinkel RK, Traczyk TN. Lipid composition and acid hydrolase content of lamellar granules of fetal rat epidermis. J Invest Dermatol. 1985 Oct;85(4):295–298. [PubMed]
  • Aszterbaum M, Menon GK, Feingold KR, Williams ML. Ontogeny of the epidermal barrier to water loss in the rat: correlation of function with stratum corneum structure and lipid content. Pediatr Res. 1992 Apr;31(4 Pt 1):308–317. [PubMed]
  • Hanley K, Rassner U, Elias PM, Williams ML, Feingold KR. Epidermal barrier ontogenesis: maturation in serum-free media and acceleration by glucocorticoids and thyroid hormone but not selected growth factors. J Invest Dermatol. 1996 Mar;106(3):404–411. [PubMed]
  • Aszterbaum M, Feingold KR, Menon GK, Williams ML. Glucocorticoids accelerate fetal maturation of the epidermal permeability barrier in the rat. J Clin Invest. 1993 Jun;91(6):2703–2708. [PMC free article] [PubMed]
  • Hanley K, Rassner U, Jiang Y, Vansomphone D, Crumrine D, Komüves L, Elias PM, Feingold KR, Williams ML. Hormonal basis for the gender difference in epidermal barrier formation in the fetal rat. Acceleration by estrogen and delay by testosterone. J Clin Invest. 1996 Jun 1;97(11):2576–2584. [PMC free article] [PubMed]
  • Hanley K, Jiang Y, Holleran WM, Elias PM, Williams ML, Feingold KR. Glucosylceramide metabolism is regulated during normal and hormonally stimulated epidermal barrier development in the rat. J Lipid Res. 1997 Mar;38(3):576–584. [PubMed]
  • Hanley K, Jiang Y, Katagiri C, Feingold KR, Williams ML. Epidermal steroid sulfatase and cholesterol sulfotransferase are regulated during late gestation in the fetal rat. J Invest Dermatol. 1997 Jun;108(6):871–875. [PubMed]
  • Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schütz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, et al. The nuclear receptor superfamily: the second decade. Cell. 1995 Dec 15;83(6):835–839. [PubMed]
  • Mangelsdorf DJ, Evans RM. The RXR heterodimers and orphan receptors. Cell. 1995 Dec 15;83(6):841–850. [PubMed]
  • Mangelsdorf DJ, Evans RM. The RXR heterodimers and orphan receptors. Cell. 1995 Dec 15;83(6):841–850. [PubMed]
  • Saitou M, Sugai S, Tanaka T, Shimouchi K, Fuchs E, Narumiya S, Kakizuka A. Inhibition of skin development by targeted expression of a dominant-negative retinoic acid receptor. Nature. 1995 Mar 9;374(6518):159–162. [PubMed]
  • Imakado S, Bickenbach JR, Bundman DS, Rothnagel JA, Attar PS, Wang XJ, Walczak VR, Wisniewski S, Pote J, Gordon JS, et al. Targeting expression of a dominant-negative retinoic acid receptor mutant in the epidermis of transgenic mice results in loss of barrier function. Genes Dev. 1995 Feb 1;9(3):317–329. [PubMed]
  • Kang S, Li XY, Voorhees JJ. Pharmacology and molecular action of retinoids and vitamin D in skin. J Investig Dermatol Symp Proc. 1996 Apr;1(1):15–21. [PubMed]
  • Keller H, Dreyer C, Medin J, Mahfoudi A, Ozato K, Wahli W. Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers. Proc Natl Acad Sci U S A. 1993 Mar 15;90(6):2160–2164. [PubMed]
  • Schoonjans K, Staels B, Auwerx J. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res. 1996 May;37(5):907–925. [PubMed]
  • Yu K, Bayona W, Kallen CB, Harding HP, Ravera CP, McMahon G, Brown M, Lazar MA. Differential activation of peroxisome proliferator-activated receptors by eicosanoids. J Biol Chem. 1995 Oct 13;270(41):23975–23983. [PubMed]
  • Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell. 1995 Dec 1;83(5):803–812. [PubMed]
  • Forman BM, Goode E, Chen J, Oro AE, Bradley DJ, Perlmann T, Noonan DJ, Burka LT, McMorris T, Lamph WW, et al. Identification of a nuclear receptor that is activated by farnesol metabolites. Cell. 1995 Jun 2;81(5):687–693. [PubMed]
  • Hurt CM, Hanley K, Williams ML, Feingold KR. Cutaneous lipid synthesis during late fetal development in the rat. Arch Dermatol Res. 1995;287(8):754–760. [PubMed]
  • Bocos C, Göttlicher M, Gearing K, Banner C, Enmark E, Teboul M, Crickmore A, Gustafsson JA. Fatty acid activation of peroxisome proliferator-activated receptor (PPAR). J Steroid Biochem Mol Biol. 1995 Jun;53(1-6):467–473. [PubMed]
  • Devchand PR, Keller H, Peters JM, Vazquez M, Gonzalez FJ, Wahli W. The PPARalpha-leukotriene B4 pathway to inflammation control. Nature. 1996 Nov 7;384(6604):39–43. [PubMed]
  • Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature. 1990 Feb 1;343(6257):425–430. [PubMed]
  • Holleran WM, Takagi Y, Menon GK, Legler G, Feingold KR, Elias PM. Processing of epidermal glucosylceramides is required for optimal mammalian cutaneous permeability barrier function. J Clin Invest. 1993 Apr;91(4):1656–1664. [PMC free article] [PubMed]
  • Correll CC, Ng L, Edwards PA. Identification of farnesol as the non-sterol derivative of mevalonic acid required for the accelerated degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J Biol Chem. 1994 Jul 1;269(26):17390–17393. [PubMed]
  • Voziyan PA, Goldner CM, Melnykovych G. Farnesol inhibits phosphatidylcholine biosynthesis in cultured cells by decreasing cholinephosphotransferase activity. Biochem J. 1993 Nov 1;295(Pt 3):757–762. [PubMed]
  • Haug JS, Goldner CM, Yazlovitskaya EM, Voziyan PA, Melnykovych G. Directed cell killing (apoptosis) in human lymphoblastoid cells incubated in the presence of farnesol: effect of phosphatidylcholine. Biochim Biophys Acta. 1994 Aug 11;1223(1):133–140. [PubMed]
  • Roullet JB, Xue H, Chapman J, McDougal P, Roullet CM, McCarron DA. Farnesyl analogues inhibit vasoconstriction in animal and human arteries. J Clin Invest. 1996 May 15;97(10):2384–2390. [PMC free article] [PubMed]
  • Holt PJ, Marks R. The epidermal response to change in thyroid status. J Invest Dermatol. 1977 May;68(5):299–301. [PubMed]
  • FELL HB, MELLANBY E. Metaplasia produced in cultures of chick ectoderm by high vitamin A. J Physiol. 1953 Mar;119(4):470–488. [PubMed]
  • Elias PM, Friend DS. Vitamin-A-induced mucous metaplasia. An in vitro system for modulating tight and gap junction differentiation. J Cell Biol. 1976 Feb;68(2):173–188. [PMC free article] [PubMed]
  • Pillai S, Bikle DD, Elias PM. Vitamin D and epidermal differentiation: evidence for a role of endogenously produced vitamin D metabolites in keratinocyte differentiation. Skin Pharmacol. 1988;1(3):149–160. [PubMed]
  • Regnier M, Darmon M. 1,25-Dihydroxyvitamin D3 stimulates specifically the last steps of epidermal differentiation of cultured human keratinocytes. Differentiation. 1991 Aug;47(3):173–188. [PubMed]
  • Schellhase DE, Emrie PA, Fisher JH, Shannon JM. Ontogeny of surfactant apoproteins in the rat. Pediatr Res. 1989 Sep;26(3):167–174. [PubMed]
  • Ballard PL. Hormonal regulation of pulmonary surfactant. Endocr Rev. 1989 May;10(2):165–181. [PubMed]
  • Fringes B, Gorgas K, Reith A. Clofibrate increases the number of peroxisomes and of lamellar bodies in alveolar cells type II of the rat lung. Eur J Cell Biol. 1988 Apr;46(1):136–143. [PubMed]
  • Lemberger T, Staels B, Saladin R, Desvergne B, Auwerx J, Wahli W. Regulation of the peroxisome proliferator-activated receptor alpha gene by glucocorticoids. J Biol Chem. 1994 Oct 7;269(40):24527–24530. [PubMed]
  • Steineger HH, Sørensen HN, Tugwood JD, Skrede S, Spydevold O, Gautvik KM. Dexamethasone and insulin demonstrate marked and opposite regulation of the steady-state mRNA level of the peroxisomal proliferator-activated receptor (PPAR) in hepatic cells. Hormonal modulation of fatty-acid-induced transcription. Eur J Biochem. 1994 Nov 1;225(3):967–974. [PubMed]
  • Imamura T, Takata I, Ogasawara M, Matsutani Y, Yamamoto T, Asagami C. [Clofibrate treatment of psoriasis with hypertriglycemia--clinical, histological and laboratory analysis]. Nihon Hifuka Gakkai Zasshi. 1991 May;101(6):623–628. [PubMed]

Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation